Sector News

UCB sells generics unit Kremers Urban for $1.53 billion

November 7, 2014
Life sciences
UCB is selling its US specialty generics business Kremers Urban Pharmaceuticals to two private equity groups for almost $1.53 billion.
 
The cash from Advent International and Avista Capital Partners will be used by Belgium-headquartered UCB “to reduce indebtedness and increase the company’s capacity strategic investments”. The deal is expected to close by the first quarter of 2015.
 
Kremers Urban focuses on difficult, ‘high-barrier-to-entry’ generics and UCB got hold of the New Jersey-based business through its acquisition of Schwarz Pharma in 2006.
 
UCB chief financial officer Detlef Thielgen said it “has been an important enabler” to build the group’s operations. However, “it’s now the right time from a value perspective to focus on our core business” of neurology and immunology.
 
The sale was announced after another Belgian firm, the over-the-counter group Omega Pharma, announced it was being acquired by Perrigo in a deal worth $4.5 billion.
 
By Kevin Grogan
 
Source: Pharma Times

Related News

June 13, 2021

Making drug-resistant bacteria susceptible to antibiotics

Life sciences

Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.

June 13, 2021

Vexed by vectors: How COVID-19 vaccine and cell and gene players are tackling the viral vector bottleneck

Life sciences

Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.

June 13, 2021

Beigene expands into cancer cell therapy with Shoreline pact

Life sciences

Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.

Send this to a friend